Nonviral Therapeutic Delivery

The Nonviral Therapeutic Delivery Committee is responsible for the development of ASGCT programming on several areas of focus. Gene therapies delivered by physical methods (electroporation, hydrodynamic delivery, ultrasound, laser) as well as newer delivery technologies such as exosomes are included. Novel RNA- and DNA-based expression vectors including transposons and integrases, minicircles, genome editors, and artificial chromosomes are a second focus. Innovative targeting methods for organ, cellular and intracellular nonviral therapeutic delivery are in the scope of the committee. Therapeutic application is emphasized using novel nonviral gene delivery methods and vectors for the treatment of genetic diseases and cancers. Finally, chimeric therapies combining viral, nonviral and cell-based methods are included.
Full NamePositionOrganizationTerm StartTerm End
Jonathan Hoggatt, PhDChairModerna Therapeutics6/1/20255/31/202747647
Stefan Radtke, PhDMemberFred Hutchinson Cancer Center6/1/20245/31/202730004
Frederic Padilla, PhDMemberFocused Ultrasound Foundation6/1/20245/31/202763065
Marxa L. Figueiredo, PhDMemberPurdue University6/1/20245/31/202713556
Maja Cemazar, PhDMemberInstitute of Oncology Ljubljana6/1/20245/31/202718544
Mihir PatelMemberEleven Independent Consulting6/1/20255/31/202889918
Negin P. Martin, PhDMemberNIEHS6/1/20245/31/202726966
Yeh-Hsing Lao, PhDMemberUniversity at Buffalo, The State University of New York6/1/20255/31/202842050
Wan Du, MD, PhDMemberMass Eye and Ear/Harvard Medical School6/1/20235/31/202946064
Chantal PICHON, PhDMemberINSERM6/1/20265/31/202973567
Samagya Banskota, PhDMemberBoston University6/1/20265/31/202983514
Mehak GuptaMemberVertex Pharmaceuticals6/1/20245/31/202768388
Jeffrey S. Bartlett, PhDMemberRampart Bioscience6/1/20245/31/202755
Mihee M. Kim, PhDMemberMMK Consulting6/1/20255/31/202847493
Danielle GaleStaff LiaisonASGCT6/1/20215/31/204535359